OverviewSuggest Edit

Synthetic Biologics is a late-stage clinical company developing therapeutics designed to preserve the microbiome. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, it is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis.

TypePublic
Founded2001
HQRockville, US
Websitesyntheticbiologics.com

Latest Updates

Employees (est.) (Feb 2019)13(-45%)
Share Price (Aug 2018)$2.6 (-8%)

Key People/Management at Synthetic Biologics

Steven Shallcross

Steven Shallcross

Interim CEO, Chief Financial Officer, Treasurer and Secretary
Joseph Sliman

Joseph Sliman

Chief Medical Officer
Michael Kaleko

Michael Kaleko

Senior Vice President, Research & Development
Raymond D. Stapleton

Raymond D. Stapleton

Senior Vice President, Manufacturing
Deb Mathews

Deb Mathews

Vice President, Medical Affairs
Show more

Synthetic Biologics Office Locations

Synthetic Biologics has an office in Rockville
Rockville, US (HQ)
9605 Medical Center Dr #270
Show all (1)

Synthetic Biologics Financials and Metrics

Synthetic Biologics Revenue

USD

Net income (FY, 2018)

(13.4m)

EBIT (FY, 2018)

(17.6m)

Market capitalization (16-Aug-2018)

276.8k

Closing stock price (16-Aug-2018)

2.6

Cash (31-Dec-2018)

28.9m
Synthetic Biologics's current market capitalization is $276.8 k.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

5.8m6.0m8.1m10.1m7.5m5.7m

R&D expense

6.5m14.5m32.9m29.1m18.8m11.8m

Operating expense total

12.3m20.5m41.0m39.3m26.3m17.6m

EBIT

(12.3m)(20.5m)(41.0m)(39.3m)(26.3m)(17.6m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

General and administrative expense

1.9m1.1m1.8m1.2m1.7m2.2m1.6m2.4m2.1m2.1m2.1m1.7m1.6m1.4m

R&D expense

1.5m2.7m2.8m3.7m6.5m7.5m10.0m8.2m7.2m7.1m6.1m4.1m3.4m3.6m

Operating expense total

3.4m3.8m4.7m4.9m8.2m9.7m11.7m10.6m9.3m9.2m8.1m5.8m5.0m5.0m

EBIT

(3.4m)(3.8m)(4.7m)(4.9m)(8.2m)(9.7m)(11.6m)(10.6m)(9.3m)(9.2m)(8.1m)(5.8m)(5.0m)(5.0m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

14.6m17.5m20.8m19.1m17.1m28.9m

Inventories

1.6m1.5m9.5m2.5m

Current Assets

16.2m19.1m30.3m21.6m17.9m29.5m

PP&E

37.0k65.0k494.0k905.0k872.0k607.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

5.1m11.2m7.8m3.3m12.0m4.8m31.8m15.1m10.0m4.5m13.5m21.1m11.0m7.1m

Current Assets

6.8m12.5m9.2m4.7m13.6m11.7m42.1m22.2m15.8m7.6m16.8m22.3m11.6m7.7m

PP&E

157.0k38.0k51.0k67.0k75.0k107.0k483.0k501.0k482.0k582.0k859.0k943.0k801.0k731.0k

Total Assets

7.0m12.5m9.3m4.7m13.7m11.8m42.6m22.7m16.3m8.2m17.7m23.3m12.5m8.4m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(12.3m)(19.8m)(44.8m)(27.8m)(15.5m)(13.4m)

Depreciation and Amortization

43.0k20.0k72.0k157.0k245.0k272.0k

Inventories

855.0k43.0k(8.0m)7.0m

Accounts Payable

(253.0k)854.0k3.4m(2.4m)27.0k(987.0k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(8.1m)(3.8m)(8.4m)(13.3m)(12.4m)(26.0m)(33.5m)(11.1m)(16.8m)(8.5m)(3.1m)(18.3m)(2.3m)(6.5m)

Depreciation and Amortization

33.0k3.0k7.0k13.0k8.0k19.0k39.0k37.0k57.0k57.0k172.0k71.0k141.0k

Accounts Payable

189.0k631.0k937.0k731.0k563.0k7.7m5.0m184.0k143.0k4.2m1.8m(895.0k)(527.0k)(803.0k)

Cash From Operating Activities

(5.0m)(3.5m)(6.8m)(11.3m)(5.5m)(12.7m)(27.9m)(5.7m)(11.5m)(6.0m)(16.3m)(6.1m)(10.4m)
USDY, 2018

Financial Leverage

2.1 x
Show all financial metrics

Synthetic Biologics Online and Social Media Presence

Embed Graph

Synthetic Biologics News and Updates

Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019

ROCKVILLE, Md., Feb. 19, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, intends to report operational highlights and financial...

Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development

ROCKVILLE, Md., Nov. 21, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has successfully completed an...

Synthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results

ROCKVILLE, Md., Nov. 8, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial ...

Synthetic Biologics to Report Third Quarter 2018 Operational Highlights and Financial Results on November 8, 2018

ROCKVILLE, Md., Oct. 30, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its...

Synthetic Biologics Announces Closing of $18,639,000 Public Offering

ROCKVILLE, Md., Oct. 15, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN) ("Synthetic Biologics" or the "Company"), a late-stage clinical company focused on developing therapeutics designed to preserve the microbiome to protect and restore the health of patients,...

Synthetic Biologics Announces Agreement with Cedars-Sinai Medical Center for an Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C

ROCKVILLE, Md., Sept. 6, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced it has entered into an agreement with...
Show more

Synthetic Biologics Frequently Asked Questions

  • When was Synthetic Biologics founded?

    Synthetic Biologics was founded in 2001.

  • Who are Synthetic Biologics key executives?

    Synthetic Biologics's key executives are Steven Shallcross, Joseph Sliman and Michael Kaleko.

  • How many employees does Synthetic Biologics have?

    Synthetic Biologics has 13 employees.

  • Who are Synthetic Biologics competitors?

    Competitors of Synthetic Biologics include Otonomy, Biogen and Shire.

  • Where is Synthetic Biologics headquarters?

    Synthetic Biologics headquarters is located at 9605 Medical Center Dr #270, Rockville.

  • Where are Synthetic Biologics offices?

    Synthetic Biologics has an office in Rockville.

  • How many offices does Synthetic Biologics have?

    Synthetic Biologics has 1 office.